Drug Approval | April 22, 2024
Zydus launches Mirabegron ER Tablets in the US
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This surgery presented unique challenges, particularly due to the size of the gallbladder and the multitude of stones
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
The collaboration between CORONA and Ferring will cater to patients across India
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Subscribe To Our Newsletter & Stay Updated
